QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hu, Y. Articles by Ingelman-Sundberg, M. Search for Related Content PubMed PubMed Citation Articles by Hu, Y. Articles by Ingelman-Sundberg, M.

This article has been cited by other articles:

				P. R. Porubsky, K. M. Meneely, and E. E. Scott Structures of Human Cytochrome P-450 2E1: INSIGHTS INTO THE BINDING OF INHIBITORS AND BOTH SMALL MOLECULAR WEIGHT AND FATTY ACID SUBSTRATES J. Biol. Chem., November 28, 2008; 283(48): 33698 - 33707. [Abstract] [Full Text] [PDF]

				Amal Al Omari and D. J. Murry Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance Journal of Pharmacy Practice, June 1, 2007; 20(3): 206 - 218. [Abstract] [PDF]

				J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]

				J.-Y. Park, K.-A. Kim, P.-W. Park, and J.-M. Ha Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe J. Clin. Pharmacol., January 1, 2006; 46(1): 109 - 114. [Abstract] [Full Text] [PDF]

				Y. Guo, Y. Zhang, Y. Wang, X. Chen, D. Si, D. Zhong, J. P. Fawcett, and H. Zhou ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS Drug Metab. Dispos., June 1, 2005; 33(6): 749 - 753. [Abstract] [Full Text] [PDF]

				J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin Heterogeneity of Toxicant Response: Sources of Human Variability Toxicol. Sci., November 1, 2003; 76(1): 3 - 20. [Abstract] [Full Text] [PDF]

				T. A. Glauser Advancing the Medical Management of Epilepsy: Disease Modification and Pharmacogenetics J Child Neurol, January 1, 2002; 17(1_suppl): S85 - S93. [Abstract] [PDF]

				D. G. McCarver ADH2 and CYP2E1 Genetic Polymorphisms: Risk Factors for Alcohol-Related Birth Defects Drug Metab. Dispos., April 1, 2001; 29(4): 562 - 565. [Abstract] [Full Text]

				M. Ingelman-Sundberg Implications of Polymorphic Cytochrome P450-Dependent Drug Metabolism for Drug Development Drug Metab. Dispos., April 1, 2001; 29(4): 570 - 573. [Abstract] [Full Text]

				S. M. Lankford, S. A. Bai, and J. A. Goldstein Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986. [Abstract] [Full Text]

				W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556. [Abstract] [Full Text]

				T. E. Jackson, P. D. Lilly, L. Recio, P. M. Schlosser, and M. A. Medinsky Inhibition of Cytochrome P450 2E1 Decreases, but Does Not Eliminate, Genotoxicity Mediated by 1,3-Butadiene Toxicol. Sci., June 1, 2000; 55(2): 266 - 273. [Abstract] [Full Text] [PDF]